Coherus Biosciences Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
228
- Stock Symbol
-
CHRS
- Investments
-
3
- Share Price
-
$0.85
- (As of Thursday Closing)
Coherus Biosciences General Information
Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Contact Information
Website
www.coherus.comCorporate Office
- 333 Twin Dolphin Drive
- Suite 600
- Redwood City, CA 94065
- United States
Corporate Office
- 333 Twin Dolphin Drive
- Suite 600
- Redwood City, CA 94065
- United States
Coherus Biosciences Timeline
Coherus Biosciences Stock Performance
As of 27-Mar-2025, Coherus Biosciences’s stock price is $0.85. Its current market cap is $98.6M with 116M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.85 | $0.90 | $0.66 - $2.61 | $98.6M | 116M | 2M | $0.25 |
Coherus Biosciences Financials Summary
As of 31-Dec-2024, Coherus Biosciences has a trailing 12-month revenue of $267M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 331,180 | 331,180 | 718,445 | 809,912 |
| Revenue | 266,960 | 266,960 | 257,244 | 211,042 |
| EBITDA | 60,941 | 60,941 | (193,939) | (255,581) |
| Net Income | 28,507 | 28,507 | (237,892) | (291,754) |
| Total Assets | 448,533 | 448,533 | 629,604 | 480,847 |
| Total Debt | 269,904 | 269,904 | 480,842 | 480,422 |
Coherus Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Coherus Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Coherus Biosciences Comparisons
Industry
Financing
Details
Coherus Biosciences Competitors (95)
One of Coherus Biosciences’s 95 competitors is Aclaris Therapeutics, a Formerly VC-backed company based in Wayne, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Valneva | Formerly VC-backed | Saint-Herblain, France | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Coherus Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Coherus Biosciences Patents
Coherus Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023242749-A1 | Methods of treating cancer | Pending | 29-Mar-2022 | ||
| EP-4499116-A1 | Methods of treating cancer | Pending | 29-Mar-2022 | ||
| AU-2023243321-A1 | Anti-ilt4 compositions and methods | Pending | 28-Mar-2022 | ||
| EP-4499144-A2 | Anti-ilt4 compositions and methods | Pending | 28-Mar-2022 | ||
| US-20230218604-A1 | Ppary agonist for treatment of progressive supranuclear palsy | Inactive | 07-Jan-2022 | A61K31/47 |
Coherus Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Coherus Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Coherus Biosciences Investments & Acquisitions (3)
Coherus Biosciences’s most recent deal was a Merger/Acquisition with Surface Oncology for . The deal was made on 08-Sep-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Surface Oncology | 08-Sep-2023 | Merger/Acquisition | Drug Discovery | ||
| Innovent Biologics (Avastin Biosimilar in Canada) | 13-Jan-2020 | Corporate Asset Purchase | Buildings and Property | ||
| InteKrin | 12-Feb-2014 | Merger/Acquisition | Pharmaceuticals |
Coherus Biosciences ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
37.38 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Coherus Biosciences Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Udenyca |
Coherus Biosciences FAQs
-
When was Coherus Biosciences founded?
Coherus Biosciences was founded in 2010.
-
Where is Coherus Biosciences headquartered?
Coherus Biosciences is headquartered in Redwood City, CA.
-
What is the size of Coherus Biosciences?
Coherus Biosciences has 228 total employees.
-
What industry is Coherus Biosciences in?
Coherus Biosciences’s primary industry is Biotechnology.
-
Is Coherus Biosciences a private or public company?
Coherus Biosciences is a Public company.
-
What is Coherus Biosciences’s stock symbol?
The ticker symbol for Coherus Biosciences is CHRS.
-
What is the current stock price of Coherus Biosciences?
As of 27-Mar-2025 the stock price of Coherus Biosciences is $0.85.
-
What is the current market cap of Coherus Biosciences?
The current market capitalization of Coherus Biosciences is $98.6M.
-
What is Coherus Biosciences’s current revenue?
The trailing twelve month revenue for Coherus Biosciences is $267M.
-
Who are Coherus Biosciences’s competitors?
Aclaris Therapeutics, Immunocore Holdings, Valneva, CytomX Therapeutics, and Inovio Pharmaceuticals are some of the 95 competitors of Coherus Biosciences.
-
What is Coherus Biosciences’s annual earnings per share (EPS)?
Coherus Biosciences’s EPS for 12 months was $0.25.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
